RNAC

Cartesian Therapeutics, Inc. Common Stock

6.82

USD

RNAC Earnings Reports

Positive Surprise Ratio

RNAC beat 18 of 38 last estimates.

47%

Next Report

Date of Next Report

Mar 11, 2026

Estimate for Q4 25 (Revenue/ EPS)

$96.56K

-$0.87

Implied change from Q3 25 (Revenue/ EPS)

-78.64%

-36.96%

Implied change from Q4 24 (Revenue/ EPS)

+25.41%

+47.46%

Cartesian Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, RNAC reported earnings of -1.38 USD per share (EPS) for Q3 25, missing the estimate of -0.86 USD, resulting in a -60.11% surprise. Revenue reached 452.00 thousand, compared to an expected 248.37 thousand, with a 81.99% difference. The market reacted with a -1.56% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.87 USD, with revenue projected to reach 96.56 thousand USD, implying an decrease of -36.96% EPS, and decrease of -78.64% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Nurix Therapeutics, Inc. Common stock

Report Date

Jan 28, 2026 For Q4 25

Estimate

-$0.88

Actual

-$0.82

Surprise

+7.66%

Regeneron Pharmaceuticals Inc

Report Date

Jan 30, 2026 For Q4 25

Estimate

$10.84

Actual

$11.44

Surprise

+5.52%

FAQ

What were Cartesian Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Cartesian Therapeutics, Inc. Common Stock reported EPS of -$1.38, missing estimates by -60.11%, and revenue of $452.00K, 81.99% above expectations.

How did the market react to Cartesian Therapeutics, Inc. Common Stock's Q3 2025 earnings?

The stock price moved down -1.56%, changed from $7.67 before the earnings release to $7.55 the day after.

When is Cartesian Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 11, 2026.

What are the forecasts for Cartesian Therapeutics, Inc. Common Stock's next earnings report?

Based on 10 analysts, Cartesian Therapeutics, Inc. Common Stock is expected to report EPS of -$0.87 and revenue of $96.56K for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.